Fred Dumais

Fred is responsible for leading Prometic’s investor relations team and is accountable for all global investor relations activity, PR and event management. He joined the company in 2001, and brings nearly twenty years of experience in investor and financial communications, as well as a deep experience of the pharmaceutical industry. He has extensive knowledge of the global financial markets in the US, Europe and his native country of Canada. Fred is a graduate from Concordia University where he gained a BA in Business Communications. He also brings to the role a background in law with a LLB from the University of Québec.

  • Prometic announces refinancing transactions

    Prometic announces refinancing transactions

    Prometic announced today its intention to enter into a series of related arrangements to restructure Prometic’s outstanding indebtedness, reduce its interest and certain other payment obligations.

    Read Article
  • Prometic reports fourth quarter and 2018 year-end financial results

    Prometic reports fourth quarter and 2018 year-end financial results

    Total revenues for 2018 of $47.4 million compared to $39.1 million in 2017 Significant increase in bioseparation 2018 revenues to $22.7 million, a 35% increase over 2017

    Read Article
  • Prometic to report its fourth quarter and 2018 year-end financial results and hold conference call / webcast

    Prometic to report its fourth quarter and 2018 year-end financial results and hold conference call / webcast

    Prometic to report its fourth quarter and 2018 year-end financial results and hold conference call / webcast

    Read Article
  • Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

    Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

    Prometic secures additional USD 5 million (CAD 6.7 million) tranche from Structured Alpha LP

    Read Article
  • Prometic secures additional USD $10 million (CAD $13.2 million) tranche from structured Alpha LP, an affiliate of Thomvest asset management

    Prometic secures additional USD $10 million (CAD $13.2 million) tranche from structured Alpha LP, an affiliate of Thomvest asset management

    Prometic announced today that it has secured an additional USD $10 million (CAD $13.2 million) tranche from Structured Alpha LP (“SALP”), an affiliate of Thomvest Asset Management Inc.

    Read Article
  • Prometic retains investment bank for strategic transactions

    Prometic retains investment bank for strategic transactions

    Prometic announced that it has engaged Lazard to review and execute key strategic transactions for the Corporation.

    Read Article
  • Prof. Simon Best appointed interim CEO of Prometic Life Sciences

    Prof. Simon Best appointed interim CEO of Prometic Life Sciences

    Prometic announced today that it has named Prof. Simon Best as Interim Chief Executive Officer, effective immediately.

    Read Article
  • Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome

    The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.

    Read Article
  • Prometic provides corporate update

    Prometic provides corporate update

    This includes a significant reduction in the Corporation’s cash use in 2019, driven by significant growth in its bioseparation revenues & a reduction of anticipated R&D expenditures by up to $30m.

    Read Article
  • Prometic reports third quarter 2018 financial results and highlights

    Prometic reports third quarter 2018 financial results and highlights

    Implementation of cost control measures to significantly reduce operational burn and extend cash runway

    Read Article
  • Prometic closes its extension of debt maturities to 2024

    Prometic closes its extension of debt maturities to 2024

    Maturity Dates of the Line of Credit and Long-Term (OID) Loans extended to September 2024

    Read Article
  • Prometic to report its third quarter 2018 financial results and hold conference call / webcast

    Prometic to report its third quarter 2018 financial results and hold conference call / webcast

    Prometic announced today that it will report its financial results for the third quarter ended September 30, 2018 on Wednesday November 14, 2018 after market close.

    Read Article
  • Prometic announces second annual plasminogen deficiency awareness week

    Prometic announces second annual plasminogen deficiency awareness week

    This initiative, sponsored by Prometic, aims to raise awareness and improve understanding of this rare disease and its effects. Plasminogen Deficiency Awareness Week is a free 4-day online event

    Read Article
  • Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA

    Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA

    Implementation plan for additional analytical assays and in-process controls confirmed and PLI finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing

    Read Article
  • Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome

    Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome

    Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).

    Read Article
  • Prometic reports second quarter 2018 financial results and highlights

    Prometic reports second quarter 2018 financial results and highlights

    Prometic has advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

    Read Article
  • Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology

    Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in journal of pharmacology

    n the ongoing Phase 2 clinical trial in patients with Alström syndrome, PBI-4050 was shown to significantly reduce liver and cardiac fibrosis.

    Read Article
  • Prometic to report its second quarter 2018 financial results and hold conference call / webcast

    Prometic to report its second quarter 2018 financial results and hold conference call / webcast

    Prometic announced today that it will report its financial results for the second quarter ended June 30, 2018 on Tuesday August 14, 2018 after market close.

    Read Article
  • Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050

    Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050

    In addition to the Rare Pediatric Disease Designation, PBI-4050 was previously granted Orphan Drug Designation by the FDA and the EMA for the treatments of AS and idiopathic pulmonary fibrosis (IPF).

    Read Article
  • Prometic conference call to present progress report on AGM corporate action plan

    Prometic conference call to present progress report on AGM corporate action plan

    Prometic it will hold a conference call on Wednesday June 27, 2018 to report on its progress in implementing the updated corporate plan presented during its AGM on Wednesday May 9th 2018.

    Read Article
  • loading
    Loading More...